The drug, nipocalimab, significantly reduced disease symptoms in a late-stage study with adult patients having myasthenia gravis, a chronic neuromuscular disorder that causes weakness in the voluntary muscle, the company announced.
Tag Archive for: clinical trial
The Swiss pharma’s fourth-quarter sales fell short of analysts’ estimates on Wednesday, as the company said it dropped a late-stage blood cancer hopeful after failing a Phase III study.
After VX-548 demonstrated significant pain relief in surgical and non-surgical settings, Vertex Pharmaceuticals is preparing to file a New Drug Application for the non-opioid candidate by mid-2024.
Bristol Myers Squibb’s PD-1 blocker Opdivo (nivolumab) failed part B of the Phase III CheckMate-914 study, bearing no significant disease-free survival benefit for patients with localized renal cell carcinoma who are at high-risk of relapse after surgery.
The blockbuster immunotherapy secured separate late-stage victories as an adjuvant-setting treatment in renal cell carcinoma and muscle-invasive urothelial carcinoma.
Saturday’s readout, which were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, could position BMS to challenge Merck’s dominant PD-1 blocker Keytruda.
The company announced today that the trial failed to show that it significantly improved survival for previously treated patients with advanced non-small cell lung cancer.
BioNTech and its partner Duality Biologics said they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca, and Daiichi Sankyo.
The Swiss pharma’s Phase III trial of ligelizumab in patients with peanut allergies has been terminated, according to a ClinicalTrials.gov update.
The biotech announced a restructuring plan as its humanized IgG1 antibody lirentelimab failed two Phase II studies in atopic dermatitis and chronic spontaneous urticaria.
